European Pharmaceutical Review

SEPTEMBER 21, 2023

Considerable progress has been made in other areas including enhancing safety, improving treatment administration and patient monitoring systems and implementing innovative pricing strategies – all with the goal of providing timely access to eligible patients who can benefit from these treatments. 2019; 70:273–288. cited 2023August].

Pharmaceutical 96

Pharmaceutical Food and Drug Administration Medicine Patients 96

pharmaphorum

SEPTEMBER 16, 2022

The week 16 data of lebrikizumab […] points towards a drug with robust efficacy with hardly any safety trade-offs. The FDA granted lebrikizumab Fast Track designation in December 2019. He explained just how promising the recent trial’s maintenance data compared to short-term data results are. Thyssen, MD, Ph.D.

Management 100

Management Side effects Patients Safety 100

Pharmaceutical Technology

SEPTEMBER 22, 2022

Invossa has demonstrated the efficacy and safety of a single shot for up to three years, as outlined by Lew in a 2019 study published in Osteoarthritis and Cartilage (NCT03383471). Similarly, ReNu also showed positive efficacy and safety for up to 12 months from a single intra-articular injection (NCT02318511, NCT03063099).

Marketing 59

Marketing Safety Physicians Management 59

Pharmaceutical Technology

JANUARY 10, 2023

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

Marketing 52

Marketing Physicians Leads Sales 52

Pharmaceutical Technology

JANUARY 23, 2023

In recent years, with the advent of biologics and novel therapeutic targets such as anti-TNF, anti-interleukin, and anti-integrin, there has been a steady increase in the number of agents approved to treat inflammatory bowel diseases (IBD), which has provided physicians with an increasing number of options to treat Crohn’s disease (CD).

Medical 59

Medical Ethics Specialization Physicians 59

Clarivate

OCTOBER 7, 2021

What’s new from ESMO: Interim efficacy and safety analysis from the randomized KEYNOTE-716 study showed that the trial met its primary endpoint of RFS, with patients receiving Keytruda presenting an RFS of 90.5% Kisqali plus letrozole demonstrated a significant OS benefit, but is that enough to displace physician favorite Ibrance?

Patients 91

Patients Safety Marketing Physicians 91

Healthcare Success

JANUARY 25, 2023

And you don’t have to search long to find stories like this: A hospital in Missouri gave their staff panic buttons after hospital staff assaults rose from 40 in 2019 to 123 in 2020—more than a 200% increase. According to the American Nurses Association, 1 in 4 nurses is assaulted on the job.

Patients 109

Patients Healthcare Healthcare Management 109

European Pharmaceutical Review

DECEMBER 19, 2023

25 In 2021 an estimated 25 million children under the age of one year did not receive basic vaccines, and the number of completely unvaccinated children increased by five million since 2019. Over his career as a physician and scientist he published 108 papers and 49 patents. 2019; 9:11409. Injection Safety Fact Sheet.

Distribution 111

Distribution Manufacturing Food Pharmaceutical 111

Pharmaceutical Technology

OCTOBER 13, 2022

In July 2019, the MHRA held up Colonis for sending a letter to physicians advertising the off-label use of the drug in children and those with renal impairment. However, the UK’s Electronic Medicines Compendium (EMC) states that “the safety and efficacy of Circadin in children aged 0 to 18 years has not yet been established.”

Prescription 59

Prescription Medicine Sales Safety 59

European Pharmaceutical Review

MARCH 11, 2024

About the author Sherene Min, MD, MPH, is Vice President of Global Clinical Development at ViiV Healthcare , a role she assumed in October 2019. With therapeutic expertise in HIV, hepatology and rare diseases, Sherene has additional expertise in clinical pharmacology and drug safety.

Medicine 98

Medicine Pharmacology Healthcare Healthcare 98

Clarivate

OCTOBER 25, 2023

of fee-for-service beneficiaries having a type 2 diabetes diagnosis in 2019 , it is among the most widespread chronic conditions in the over-65 population. Unlike in Part D, Part B drugs are physician administered and there is less certainty regarding which drugs will be tapped for negotiations (i.e., With 27.5%

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

APRIL 7, 2023

Importance of Data Collection Many manufacturers fail to allocate sufficient time to obtain the safety and efficacy data needed to define critical endpoints. The accumulation of the right data—including safety, efficacy, and outcomes—are vital to negotiations with payers as opposed to what regulators are looking for.

Manufacturing 52

Manufacturing Marketing Patients Safety 52

Clarivate

MAY 24, 2022

Approval pathways have been established that allow manufacturers to bring innovative therapies to market without conducting trials in Mainland China, provided the safety and efficacy of the drugs have been demonstrated through real world data (RWD) in other markets. 2019; 2:8-15. (in 10] [11] [12]. 10] [11] [12]. The Lancet.

Patients 52

Patients Food and Drug Administration Marketing Pharma 52

PM360

DECEMBER 14, 2022

The launch of Amazon Clinic is happening as Amazon Care, a hybrid suite of urgent care and primary care services piloted with Amazon employees and their families in the Seattle region in 2019, shuts down. billion in 2019. As Dr. Ayogu referred to, Amazon is also in the midst of a $3.9 Pfizer’s Giant Ireland Investment.

Medical 52

Medical Manufacturing Healthcare Healthcare 52

Contrarian Sales Techniques

FEBRUARY 25, 2023

The film features interviews with activists, physicians, and other experts who discuss the challenges and injustices that arose from the AIDS epidemic and the global response. However, there are still challenges, such as ensuring the quality and safety of generic drugs, as well as educating the public about their benefits.

Marketing 52

Marketing Distribution Medical Government 52

Clarify Health

JULY 27, 2020

Now with the appropriate safety measures in place, they are urging patients to come back. Safety is the new quality,” Jennifer said. Ascension conducted 7k virtual visits between March and May 2019; this year, telehealth visits spiked to 700k during those same two months. However, maybe not all deferred care needs to return.

Healthcare 52

Healthcare Healthcare Patients Safety 52

Clarify Health

FEBRUARY 10, 2022

Having access to precise and comprehensive SDoH insights and physician referral patterns enables pinpointing of diverse patient cohorts that meet a clinical trial’s eligibility criteria and needs. They developed an inclusive health literacy glossary to aid clinical investigators and researchers.

Recruitment 52

Recruitment Patients Education Training 52

Clarivate

OCTOBER 10, 2022

Fruquintinib was well-tolerated, with a safety profile consistent with that previously reported in other studies. The question of which KRAS inhibitor is most effective remains elusive, although being first to market in addition to strong efficacy and safety data could differentiate the more competitive agent. Market impact.

Marketing 52

Marketing Safety Patients Competition 52

Infuse Medical

MARCH 1, 2023

Anytime knowledge gets transferred to a sales rep, or a clinician, a physician or a patient, the purpose is to increase patient outcomes or to lower costs…Both of which ultimately leads to getting better healthcare solutions to as many people as possible. Today, there are over 170 Million VR headsets being used!

Training 52

Training Education Leads Sales 52

pharmaphorum

OCTOBER 26, 2022

Chiesi has proven its dedication to global public health through its designation as a certified Benefit Corporation (B Corp) since 2019. This design will enable physicians to take more informed and robust treatment decisions than in most other cases,” Chiesi said. The company aims at becoming net-zero by 2035.

Patients 96

Patients Pharma Consulting Transportation 96